Log in
Enquire now
‌

US Patent 11672826 Methods of treating aging-related disorders

Patent 11672826 was granted and assigned to HCW Biologics Inc. on June, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
HCW Biologics Inc.
HCW Biologics Inc.
0
Date Filed
August 30, 2019
0
Date of Patent
June 13, 2023
0
Patent Application Number
16557875
0
Patent Citations
‌
US Patent 7612181 Dual variable domain immunoglobulin and uses thereof
0
‌
US Patent 7691380 Combined methods for tumor coagulation and tumor treatment
0
‌
US Patent 7968094 Use of anti-tissue factor antibodies for treating thromboses
0
‌
US Patent 8133485 Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof
0
‌
US Patent 8217149 Anti-PD-L1 antibodies, compositions and articles of manufacture
0
‌
US Patent 8258268 Dual variable domain immunoglobulin and uses thereof
0
‌
US Patent 8552156 Anti-TIM-3 antibody
0
‌
US Patent 8586714 Dual variable domain immunoglobulins and uses thereof
0
‌
US Patent 8735546 Dual variable domain immunoglobulins and uses thereof
0
‌
US Patent 8741604 Nucleic acid molecule encoding a specific IL-1R1 antibody
0
•••
Patent Citations Received
‌
US Patent 12115191 Methods of treating age-related and inflammatory diseases
0
‌
US Patent 11987619 Single-chain chimeric polypeptides and uses thereof
0
‌
US Patent 12018071 Single-chain chimeric polypeptides and uses thereof
0
‌
US Patent 12024545 Methods of treating aging-related disorders
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11672826
0
Patent Primary Examiner
‌
Zachary S Skelding
0

Find more entities like US Patent 11672826 Methods of treating aging-related disorders

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.